盐酸巴尼地平(Barnidipine Hydrochloride) - 药物靶点：Cav2.1_在研适应症：肾血管性高血压，肾实质性高血压，高血压_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Barnidipine、Barnidipine hydrochloride (JAN)、Cyress

+ [15]

靶点

Cav2.1

作用机制

Cav2.1抑制剂(calcium voltage-gated channel subunit alpha1 A inhibitors)

治疗领域

心血管疾病泌尿生殖系统疾病

在研适应症

肾血管性高血压肾实质性高血压高血压

非在研适应症-

原研机构

Japan Established Medicine Corp

在研机构

LTL Pharma Co., Ltd.

Daiichi Sankyo Co., Ltd.Japan Established Medicine Corp

+ [1]

非在研机构-

最高研发阶段批准上市

首次获批日期

日本 (1992-01-01),

高血压

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构

分子式C27H30ClN3O6

InChIKeyXEMPUKIZUCIZEY-YSCHMLPRSA-N

CAS号104757-53-1

查看全部结构式(2)

关联

3

项与盐酸巴尼地平相关的临床试验

EUCTR2007-004938-16-IT / Not yet recruitingN/A

A RANDOMISED, DOUBLE-BLIND STUDY TO COMPARE THE EFFECT ON SYMPATHETIC ACTIVITY AND HEMODYNAMIC PROFILE OF BARNIDIPINE AND AMLODIPINE IN PATIENTS WITH MILD TO MODERATE ESSENTIAL HYPERTENSION. - ND

开始日期2008-02-19

申办/合作机构

Astellas Pharma Europe BV

EUCTR2006-001469-41-IT / Not yet recruitingN/AIIT

Randomized, open label, multicenter ABPM study to evaluate the effects of barnidipine as add-on therapy in patients with hypertension not adequately controlled on therapy with losartan - ND

开始日期2006-08-11

申办/合作机构

Istituto Auxologico Italiano

EUCTR2005-004288-47-BE / Not yet recruiting临床4期IIT

Etude des effets d'un antagoniste calcique(la barnidipine) sur la sensibilité des chémorécepteurs et l'activité orthosympathique.

开始日期2005-10-04

申办/合作机构

Hôpital Erasme

100 项与盐酸巴尼地平相关的临床结果

登录后查看更多信息

100 项与盐酸巴尼地平相关的转化医学

登录后查看更多信息

100 项与盐酸巴尼地平相关的专利（医药）

登录后查看更多信息

104

项与盐酸巴尼地平相关的文献（医药）

2022-01-01·Biomedical Chromatography4区 · 医学

Exploring an experimental combination of analytical quality by design and green analytical chemistry approaches for development of HPTLC densitometric protocol for the analysis of barnidipine hydrochloride

4区 · 医学

Article

作者: Chaudhari, Suraj R. ; Shirkhedkar, Atul A.

AbstractAn experimental combination of analytical quality by design and green analytical chemistry approaches is introduced to develop an high‐performance thin‐layer chromatography (HPTLC) approach to quantify barnidipine hydrochloride in the pharmaceutical matrix. The analytical quality by design approach was introduced to green analytical chemistry to enhance protocol knowledge while ensuring efficiency and reducing environmental impacts, energy consumption and analyst visibility. This analytical approach was systematically addressed by exploring failure mode effect analysis, risk assessment and optimization design. Subsequently, a screening of primary variables was performed to select the aptest proportion of solvents in the mobile phase resulting from the principles of green analytical chemistry. Failure mode effect analysis and a risk assessment study were attempted to estimate the critical method parameters (CMPs). The influence of the CMPs on critical analytical attributes, i.e. retention factor and peak area, was assessed through a screening design. A response surface methodology was then executed for the critical analytical attributes as a concern of the determined CMPs, and the conditions for excellent resolution were determined using a desirability procedure. The established protocol was validated in compliance with the International Conference on Harmonization guideline Q2(R1) and showed excellent specificity and sensitivity.

2021-08-01·Future Medicinal Chemistry4区 · 医学

Computational Drug Repositioning for Ischemic Stroke: Neuroprotective Drug Discovery

4区 · 医学

Article

作者: Chen, Xiujie ; Bender, Andreas ; Zhang, Yan ; Meng, Qingkang ; Li, Yunong ; Yang, Jingbo

Background: A comprehensive approach to drug repositioning will be required to overcome translational hurdles and identify more neuroprotective drugs. Results & methods: Gene Set Enrichment Analysis was applied to identify related pathways and enriched genes. Candidate genes were optimized using ToppGene, ToppGenet and pBRIT. From the perspective of the local structures, gene–domain–substructure–drug relationships were constructed. Using the MCODE algorithm and K-means clustering, 31 functional subnetworks were obtained, and 252 drugs with proposed neuroprotective function were identified. Using computational analysis, 72 substructures with different scores were found to correspond to neuroprotective functions. The protective effects of benidipine and barnidipine were confirmed in vitro. Conclusion: The authors' research has great potential to discover more neuroprotective drugs and obtain more information regarding mechanisms of action and functional substructures.

2021-01-01·Archives of Medical Research4区 · 医学

Targeting SARS-CoV-2 Main Protease: A Computational Drug Repurposing Study

4区 · 医学

Article

作者: Baby, Krishnaprasad ; Nayak, Usha Y ; Suresh, Akhil ; Nayak, Yogendra ; Maity, Swastika ; Mehta, Chetan H

BACKGROUND AND AIMSSevere Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) induced Novel Coronavirus Disease (COVID-19) has currently become pandemic worldwide. Though drugs like remdesivir, favipiravir, and dexamethasone found beneficial for COVID-19 management, they have limitations clinically, and vaccine development takes a long time. The researchers have reported key proteins which could act as druggable targets. Among them, the major protease M^pro is first published, plays a prominent role in viral replication and an attractive drug-target for drug discovery. Hence, to target M^pro and inhibit it, we accomplished the virtual screening of US-FDA approved drugs using well-known drug repurposing approach by computer-aided tools.METHODSThe protein M^pro, PDB-ID 6LU7 was imported to Maestro graphical user interphase of Schrödinger software. The US-FDA approved drug structures are imported from DrugBank and docked after preliminary protein and ligand preparation. The drugs are shortlisted based on the docking scores in the Standard Precision method (SP-docking) and then based on the type of molecular interactions they are studied for molecular dynamics simulations.RESULTSThe docking and molecular interactions studies, five drugs emerged as potential hits by forming hydrophilic, hydrophobic, electrostatic interactions. The drugs such as arbutin, terbutaline, barnidipine, tipiracil and aprepitant identified as potential hits. Among the drugs, tipiracil and aprepitant interacted with the M^pro consistently, and they turned out to be most promising.CONCLUSIONSThis study shows the possible exploration for drug repurposing using computer-aided docking tools and the potential roles of tipiracil and aprepitant, which can be explored further in the treatment of COVID-19.

100 项与盐酸巴尼地平相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01104	盐酸巴尼地平	C08CA12	DB09227

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
肾血管性高血压	日本	LTL Pharma Co., Ltd.	1994-09-07
肾实质性高血压	日本	LTL Pharma Co., Ltd.	1992-07-03
高血压	日本	Japan Established Medicine Corp	1992-01-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


EULAR2024	N/A	系统性硬皮病	-	Barnidipine 10mg/day	遞膚壓鏇顧鏇鏇獵襯鏇(構壓鑰鹽觸窪簾簾壓襯) = The two groups had a similar incidence of AEs leading to discontinuation (20.1 vs 17%), the most commonly reported being headache (38.5%), hypotension (30.8%), palpitations, flushing, and edema (7.7% each). No serious AE was reported in any group. 憲願醖壓選遞鏇獵積鑰 (糧鹽繭蓋繭築選衊鹹蓋 )	-	2024-06-05
				MR-nifedipine 20mg/day
ASN2014	N/A	高血压 aldosterone \| renin \| cortisol ... 更多	-	Spironolactone 50mg	(餘蓋網範壓構淵餘衊壓) = 築積廠構餘繭積夢夢餘積繭艱鏇鬱餘糧夢艱壓 (憲鏇積構觸構餘獵鑰餘, 10.8)	积极	2014-11-11
				Barnidipine 15mg	(餘蓋網範壓構淵餘衊壓) = 遞鬱齋製鬱顧鹹蓋鹹蓋積繭艱鏇鬱餘糧夢艱壓 (憲鏇積構觸構餘獵鑰餘, 13.8)